AGLE - Aeglea BioTherapeutics, Inc.

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Currency in USD
Earnings estimateCurrent qtr. (Jun 2023)Next qtr. (Sep 2023)Current year (2023)Next year (2024)
No. of analysts1111
Avg. Estimate-0.15-0.08-0.47-0.08
Low estimate-0.15-0.08-0.47-0.08
High estimate-0.15-0.08-0.47-0.08
Year ago EPS-0.27-0.19-0.99-0.47
Revenue estimateCurrent qtr. (Jun 2023)Next qtr. (Sep 2023)Current year (2023)Next year (2024)
No. of analysts1112
Avg. Estimate200k200k790k1.05M
Low estimate200k200k790kN/A
High estimate200k200k790k2.1M
Year ago sales625k174k2.33M790k
Sales growth (year/est)-68.00%14.90%-66.10%32.90%
Earnings history29/06/202229/09/202230/12/202230/03/2023
Est. EPS-0.31-0.23-0.2-0.18
Actual EPS-0.27-0.19-0.18-0.2
Difference0.040.040.02-0.02
Surprise %12.90%17.40%10.00%-11.10%
EPS trendCurrent qtr. (Jun 2023)Next qtr. (Sep 2023)Current year (2023)Next year (2024)
Current estimate-0.15-0.08-0.47-0.08
7 days ago-0.12-0.05-0.41-0.09
30 days ago-0.14-0.07-0.53-0.28
60 days ago-0.17-0.17-0.73-0.68
90 days ago-0.19-0.19-0.75-0.55
EPS revisionsCurrent qtr. (Jun 2023)Next qtr. (Sep 2023)Current year (2023)Next year (2024)
Up last 7 daysN/AN/AN/AN/A
Up last 30 days1111
Down last 7 daysN/AN/AN/AN/A
Down last 30 daysN/AN/AN/AN/A
Growth estimatesAGLEIndustrySector(s)S&P 500
Current qtr.44.40%N/AN/AN/A
Next qtr.57.90%N/AN/AN/A
Current year52.50%N/AN/AN/A
Next year83.00%N/AN/AN/A
Next 5 years (per annum)N/AN/AN/AN/A
Past 5 years (per annum)N/AN/AN/AN/A